Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Healthtrust
Covington
Citi
Novartis
Boehringer Ingelheim
Dow
Johnson and Johnson
US Department of Justice
AstraZeneca

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020976

« Back to Dashboard

NDA 020976 describes OPTIMARK IN PLASTIC CONTAINER, which is a drug marketed by Liebel-flarsheim and is included in one NDA. It is available from one supplier. Additional details are available on the OPTIMARK IN PLASTIC CONTAINER profile page.

The generic ingredient in OPTIMARK IN PLASTIC CONTAINER is gadoversetamide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the gadoversetamide profile page.
Summary for 020976
Tradename:OPTIMARK IN PLASTIC CONTAINER
Applicant:Liebel-flarsheim
Ingredient:gadoversetamide
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020976
Suppliers and Packaging for NDA: 020976
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OPTIMARK IN PLASTIC CONTAINER gadoversetamide INJECTABLE;INJECTION 020976 NDA Liebel-Flarsheim Company LLC 0019-1177 N 0019-1177-50
OPTIMARK IN PLASTIC CONTAINER gadoversetamide INJECTABLE;INJECTION 020976 NDA Liebel-Flarsheim Company LLC 0019-1177 N 0019-1177-16

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength9927MG/30ML (330.9MG/ML)
Approval Date:Dec 8, 1999TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength3309MG/10ML (330.9MG/ML)
Approval Date:Dec 8, 1999TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength4963.5MG/15ML (330.9MG/ML)
Approval Date:Dec 8, 1999TE:RLD:Yes

Expired US Patents for NDA 020976

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIMARK IN PLASTIC CONTAINER gadoversetamide INJECTABLE;INJECTION 020976-001 Dec 8, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim OPTIMARK IN PLASTIC CONTAINER gadoversetamide INJECTABLE;INJECTION 020976-001 Dec 8, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Federal Trade Commission
Harvard Business School
Chubb
Colorcon
Baxter
Cipla
Queensland Health
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot